Exclusive Online Content
Immutep Enters Into New Collaboration With Merck KGaA
Immutep Limited recently announced a new collaboration and supply agreement with Merck KGaA , Darmstadt, Germany, for a Phase 1/2a clinical trial in patients with….
Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline Into Cancer & Fibrotic Diseases
Corbus Pharmaceuticals Holdings, Inc. recently announced licensing deals for two new monoclonal antibodies (mAbs), CRB-601 and CRB-602, that target integrins to inhibit activation of….
Aptamer Group Collaborates With World-Leading Pharmaceutical Company to Evaluate Optimer Technology
Aptamer Group recently announced that it has signed an agreement with the multinational pharmaceutical and biopharmaceutical company Takeda Pharmaceutical Company Limited…..
EXECUTIVE INTERVIEW – Poseida Therapeutics: Creating the Next Wave of Cell & Gene Therapies With the Capacity to Cure
Eric M. Ostertag, MD, PhD, Chief Executive Officer of Poseida Therapeutics, discusses the company’s innovative approach to develop safer, more effective, accessible and affordable cell and gene therapies for patients.
Microfluidics: An Alternative Method for Developing Nanoparticle Drug Delivery Systems
The encapsulation of drugs within purposely formulated liposome nanoparticles offers the potential for more controlled and sustained release, as well as reducing toxicity and….
Stevanato Group & Corning Incorporated Sign Licensing Agreement to Offer Corning Valor Glass Vials in Presterilized SG EZ-fill Packaging Configuration
Stevanato Group recently announced a licensing agreement with Corning Incorporated to offer a combined solution that will provide biopharmaceutical companies with improved levels of….
Evonik Markets New Enteric-Protected Ready-to-Fill Capsules for Fast, High-Performance Drug Development
Evonik recently launched the EUDRACAP platform of easy-to-handle capsules to help the pharmaceutical industry accelerate speed to market for complex oral drug products in early development stages…..
Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions
Myriad Genetics, Inc. recently announced it has signed a definitive agreement to sell Myriad RBM, Inc. to Q2 Solutions, a leading global clinical trial laboratory services organization….
Ginkgo Bioworks & Biogen Announce Collaboration & License Agreement to Develop Novel Gene Therapy Manufacturing Platform
Ginkgo Bioworks and Biogen recently announced a gene therapy collaboration in which the companies aim to redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors…..
Phillips-Medisize Unveils Aria Smart Autoinjector Platform to Drive Innovation & Sustainability in Digital Drug Delivery
Phillips-Medisize, a Molex company and leader in drug delivery, diagnostic, and MedTech devices, recently unveiled the Aria Smart Autoinjector platform to unlock innovation, differentiation, and sustainability in the digital drug-delivery device market….
EXCLUSIVE ONLINE CONTENT
Evonik & Stanford University Sign Research Collaboration: Evonik to Market & Develop New Drug Delivery Platform for mRNA & Gene Therapy
Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs)…..
Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement With Gilead Sciences
Jounce Therapeutics, Inc. recently announced the US FDA clearance of its Investigational New Drug (IND) application for JTX-1811, an anti-CCR8 antibody, for which Gilead Sciences, Inc. has exclusive rights….
iTeos Therapeutics & GSK Announce Development & Commercialization Collaboration
iTeos Therapeutics and GlaxoSmithKline plc recently announced an agreement to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody currently in Phase 1 development as a….
VERAXA Biotech & Quadira Biosciences Enter Partnership on ADC Development
VERAXA Biotech GmbH recently announced it has entered into a partnership agreement with Quadira Biosciences AG, Zug, Switzerland, to jointly develop a suite of novel ADCs for the….
Liminatus Pharma R&D Consortium Companion Diagnostic YN 1203 Demonstrates ~70% Sensitivity & Specificity in Clinical Testing
Liminatus Pharma recently announced its companion diagnostic to support checkpoint inhibitor therapies, YN1203 CDx liquid biopsy test (YN1203 ELISA Kit), has demonstrated….